Harmony Biosciences Holdings Stock Performance
| HRMY Stock | USD 34.07 0.84 2.53% |
The company retains a Market Volatility (i.e., Beta) of 1.05, which attests to a somewhat significant risk relative to the market. Harmony Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Harmony Biosciences is expected to follow. Harmony Biosciences right now retains a risk of 3.88%. Please check out Harmony Biosciences treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Harmony Biosciences will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Harmony Biosciences Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong primary indicators, Harmony Biosciences is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 2.52 | Five Day Return 7.64 | Year To Date Return 13.45 | Ten Year Return (5.62) | All Time Return (5.62) |
1 | Disposition of 8013 shares by Kapadia Sandip of Harmony Biosciences at 33.58 subject to Rule 16b-3 | 09/13/2024 |
2 | Did Harmony Biosciences Holdings, Inc. Mislead Investors Shareholder Rights Advocates at Levi Korsinsky Investigate - HRMY | 10/07/2024 |
3 | Harmony Biosciences Q3 2024 Earnings EPS of 0.79 Beats Estimates, Revenue Hits 186 Million | 10/29/2024 |
4 | Harmony Biosciences prices secondary offering at 31 per share | 10/31/2024 |
5 | Are Investors Undervaluing Harmony Biosciences Right Now | 11/01/2024 |
6 | Levi Korsinsky Reminds Shareholders of an Investigation into Harmony Biosciences Holdings, Inc. Regarding Potential Securities Fraud Allegations | 11/04/2024 |
7 | Harmony Biosciences Holdings, Inc. is AlphaCentric Advisors LLCs 2nd Largest Position | 11/05/2024 |
8 | ATTENTION Harmony Biosciences Holdings, Inc. Investors You May Have Been Affected by Fraud- Contact Levi Korsinsky to Discuss Your Rights | 11/06/2024 |
9 | Harmony Biosciences Holdings, Inc. Investigation Ongoing Contact Levi Korsinsky About Potential Securities Fraud Allegations - HRMY | 11/08/2024 |
10 | An Investigation Has Commenced on Behalf of Harmony Biosciences Holdings, Inc. Shareholders. Contact Levi Korsinsky to Discuss your HRMY Losses. | 11/13/2024 |
11 | Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi Korsinsky Regarding Potential Securities Law Vio... | 11/20/2024 |
| Begin Period Cash Flow | 244.5 M |
Harmony |
Harmony Biosciences Relative Risk vs. Return Landscape
If you would invest 3,562 in Harmony Biosciences Holdings on August 27, 2024 and sell it today you would lose (155.00) from holding Harmony Biosciences Holdings or give up 4.35% of portfolio value over 90 days. Harmony Biosciences Holdings is currently generating 0.0068% in daily expected returns and assumes 3.8784% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Harmony, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Harmony Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Harmony Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Harmony Biosciences Holdings, and traders can use it to determine the average amount a Harmony Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0017
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HRMY |
Estimated Market Risk
| 3.88 actual daily | 34 66% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Harmony Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Harmony Biosciences by adding Harmony Biosciences to a well-diversified portfolio.
Harmony Biosciences Fundamentals Growth
Harmony Stock prices reflect investors' perceptions of the future prospects and financial health of Harmony Biosciences, and Harmony Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Harmony Stock performance.
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 1.72 B | ||||
| Shares Outstanding | 57.03 M | ||||
| Price To Earning | 293.37 X | ||||
| Price To Book | 3.26 X | ||||
| Price To Sales | 2.85 X | ||||
| Revenue | 582.02 M | ||||
| Gross Profit | 354.37 M | ||||
| EBITDA | 216.39 M | ||||
| Net Income | 128.85 M | ||||
| Cash And Equivalents | 254.17 M | ||||
| Cash Per Share | 4.30 X | ||||
| Total Debt | 193.57 M | ||||
| Debt To Equity | 0.79 % | ||||
| Current Ratio | 4.91 X | ||||
| Book Value Per Share | 10.46 X | ||||
| Cash Flow From Operations | 219.39 M | ||||
| Earnings Per Share | 2.11 X | ||||
| Market Capitalization | 1.94 B | ||||
| Total Asset | 811.45 M | ||||
| Retained Earnings | (143.28 M) | ||||
| Working Capital | 287.29 M | ||||
About Harmony Biosciences Performance
Evaluating Harmony Biosciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Harmony Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Harmony Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 16.15 | 15.34 | |
| Return On Tangible Assets | 0.19 | 0.20 | |
| Return On Capital Employed | 0.30 | 0.31 | |
| Return On Assets | 0.16 | 0.17 | |
| Return On Equity | 0.28 | 0.26 |
Things to note about Harmony Biosciences performance evaluation
Checking the ongoing alerts about Harmony Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Harmony Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Harmony Biosciences had very high historical volatility over the last 90 days | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from accesswire.com: Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi Korsinsky Regarding Potential Securities Law Violations - HRMY |
- Analyzing Harmony Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Harmony Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Harmony Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Harmony Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Harmony Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Harmony Biosciences' stock. These opinions can provide insight into Harmony Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Harmony Stock Analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.